


FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PW FORM PAT-1449)
Patent and Trademark Office



Atty.
Dkt. No.

M#

Client Ref.

0280728

2000-35-053A

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant: Mitchell Reff

APR 11 2003

Appln. No.: 09/982,845

TECH CENTER 1600/2900

Filing Date: October 22, 2001

Examiner: TBA

Group Art Unit: 1644

Date: April 8, 2003

Page 1 of 2

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
AR						

FOREIGN PATENT DOCUMENTS


		Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract		Translation Readily Available	
						Enclosed	No	Enclos	No
✓	BR	WO 99/54342	10/1999	PET WO	Umana et al.				
✓	CR	WO 98/37099	08/1998	PET WO	Reff et al.				
✓	DR	WO 00/27433	05/2000	PET WO	Grillo-Lopez et al.				
	ER								

OTHER (including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

✓	FR	Grillo-Lopez et al., "Rituximab: The First Monoclonal Antibody Approved for the Treatment of Lymphoma", Current Pharmaceutical Biotechnology 1:1-9 (2000)						
✓	GR	Jiang et al., "Enhanced Effector Functions of Dimeric Forms of IDEC-C2B8 (rituximab)", Blood, 92:86A, Abstract # 376 (1999)						
✓	HR	Czuczman et al., "Treatment of Patients With Low-Grade B-Cell Lymphoma With the Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy", Journal of Clinical Oncology, 17:268-276 (1999)						
✓	IR	Davis et al., "Combination Immunotherapy of Low Grade or Follicular (LG/F) Non-Hadgkins Lymphoma (NHL) with Rituximab and Alpha Interferon: Interim Analysis", Proc Annu Meet Am Soc Clin Oncol, 17:A39 (1998)						
✓	JR	Flinn et al., "In Vivo Purging and Adjuvant Immunotherapy with Rituximab During PBSC Transplant for NHM", Blood 92:648A, Abstract # 2673 (1998)						
✓	KR	Davis et al., "Rituximab: Phase II (PII) Retreatment (ReRx) Study in Patients (PTS) with Low-Grade or Follicular (LG/F) NHL", Blood 92:414A, Abstract #1710 (1998)						
✓	LR	Van der Kolk et al., "Chimeric Anti-CD20 Monoclonal Antibody (Rituximab) Plus G-CSF in Relapsed B-Cell Lymphoma: A Phase I/II Clinical Trial", British Journal of Heamatology 102:243, Abstract #4037 (1998)						
✓	MR	Press et al., "A Phase I/II Trial of High Dose Iodine-131-Anti-B1 (Anti-CD20) Monoclonal Antibody, Etoposide, Cyclophosphamide, and Autologous Stem Cell Transplantation for Patients with Relapsed B-Cell Lymphomas", Proc Annu Meet Am Soc Clin Oncol, 17:A509 (1998)						
✓	NR	Davis et al., "Retreatments with Rituxan (Rituximab, IDEC-C2B8) have significant efficacy, do not cause hama, and are a viable minimally toxic alternative in relapsed or refractory non-Hodgkin's lymphoma (NHL)", Blood, 90:509a (1997)						
✓	OR	Wahl et al., "Successful Re-Treatment of Non-Hodgkin's Lymphoma (NHL) with Iodine-131 Anti-B1 Antibody", Proc Annu Meet Soc Clin Oncol, 17:A156 (1998)						

[Handwritten signature]

9/11/2003



PR	Press, Oliver W., "Prospects for the Management of Non-Hodgkin's Lymphomas with Monoclonal Antibodies and Immunoconjugates", The Cancer Journal from Scientific American, 4:S19-S26 (1988)				
RR	Kuzel et al., "A Phase I Escalating-Dose Safety, Dosimetry and Efficacy Study of Radiolabeled Monoclonal Antibody LYM-1", Cancer Biotherapy, 8:3-16 (1993)				
RR	Knox et al., "Yttrium-90-labeled Anti-CD20 Monoclonal Antibody Therapy of Relapsed B-Cell Lymphoma", Clinical Cancer Research, 3:457-470 (1996)				
SR	McLaughlin et al., "Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program", Journal of Clinical Oncology, 16:2825-2833 (1998)				
TR	Maloney et al., "IDEC-C2B8: Results of a Phase I Multiple-Dose Trial in Patients with Relapsed Non-Hodgkin's Lymphoma", Journal of Clinical Oncology, 15:3266-3274 (1997)				
UR	Van der Kolk et al., "Chimeric Anti-CD20 Monoclonal Antibody (Rituximab) Plus G-CSF in Relapsed B-Cell Lymphoma: A Phase I/II Clinical Trial", Blood, 92:241B (1998)				

RECEIVED

APR 11 2003

TECH CENTER 1600/2900

Examiner [Signature] Date Considered: 9/11/2005

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PW FORM PAT-1449)
Patent and Trademark Office

Atty.
Dkt. No.


M#

Client Ref.

0280728

2000-30-0513A

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**



Applicant: MITCHELL REFF

Appln. No.: 09/982,849

Filing Date: October 22, 2001

Examiner: R. Schwadron

Group Art Unit: 1644

Date: December 24, 2003 Page 1 of 1

U.S. PATENT DOCUMENTS

Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date
MS	AR	6,183,744 B1	02/2001	GOLDENBERG			
M	BR	6,306,393 B1	10/2001	GOLDENBERG			
	CR						
	DR						
	ER						
	FR						

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available
	GR						
	HR						
	IR						
	JR						
	KR						

OTHER

MR	LR	Kaminski, et al., "Radioimmunotherapy of Advanced B-Cell Lymphoma with Non Bone Marrow Ablative Doses of 131-I MB-1 Antibody," 1990, <i>Antibody Immunoconjugates, and Radiopharmaceuticals</i> , Vol. 3, No. 1, Abstract No. 83.
	MR	Kaminski, et al., "Radioimmunodetection (RID) and Non Marrow Ablative Radioimmunotherapy (RIT) of B-Cell Lymphoma With 131-I MB-1 Antibody," 1990, <i>Proceedings of ASCO</i> , Vol. 9, p. 271, Abstract No. 1051.
	NR	Wahl, et al., "Radioimmunotherapy of B-Cell Lymphoma with 131 MB-1 Monoclonal Antibody," <i>The Journal of Nuclear Medicine: Proceedings of the 37th Annual Meeting</i> , p. 852, Abstract No. 622.
	OR	Kaminski, et al., "Phase I Trial Results of 131-I MB-1 Antibody Radioimmunotherapy (RAIT) of B-Cell Lymphoma," 1990, <i>Antibody Immunoconjugates, and Radiopharmaceuticals</i> , Vol. 4, No. 1, p. 36, Abstract No. 66.
	PR	Kaminski, et al., "Phase I Evaluation of 131-I MB-1 Antibody Radioimmunotherapy (RIT) of B-Cell Lymphoma," 1990, <i>Blood</i> , Vol. 76, No. 10, p. 355a, Abstract No. 1409.
	QR	Kaminski, et al., "Imaging, Dosimetry, and Radioimmunotherapy With Iodine 131-Labeled Anti-CD37 Antibody in B-Cell Lymphoma," 1992, <i>Journal of Clinical Oncology</i> , Vol. 10, No. 11, pp. 1696-1711.
	RR	Jensen, et al., "Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC C2B8, rituximab)," 1998, <i>Ann Hematol</i> , Vol. 77, pp. 89-91.
	SR	
	TR	

Examiner

Date Considered:

1/14/2003

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT


Applicant: MITCHELL REFF

Appln. No.: 09/982,849

Filing Date: October 22, 2001

Examiner: R. Schwadron Group Art Unit: 1644

Date: June 14, 2003



Page 1 of 2

U.S. PATENT DOCUMENTS

Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Subclass
MS	AR	4,816,567	03/1989	Cabilly	-	-
	BR	5,500,362	03/1996	Robinson	-	-
	CR	5,595,721	01/1997	Kaminski	-	-
	DR	5,677,180	10/1997	Robinson	-	-
	ER	5,721,108	02/1998	Robinson	-	-
	FR	5,736,137	04/1998	Anderson	-	-
	GR	5,776,456	07/1998	Anderson	-	-
	HR	5,843,439	12/1998	Anderson	-	-

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available
	IR						
	JR						
	KR						
	LR						
	MR						

OTHER (including in this order: Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

MS	NR	Idex Pharmaceuticals and Corixa Corp., Case No. 01-1637-IEG [Doc. Nos. 486, 584] (S.D. Cal. Oct. 14, 2003).				
	OR	Biogen Idec v. Corixa Corp., Case No. 01-1637-IEG [Doc. Nos. 635, 662, 486] (S.D. Cal. Jan. 22, 2004).				
	PR	Cook et al., "Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation," <i>Lancet</i> , 1999, 354(9191):1698-1699.				
	QR	Demidem et al., "Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs," <i>Cancer Biother Radiopharm</i> , 1997, 12(3):177-186.				
	RR	Hoffman et al., "Bone marrow remission of hairy cell leukaemia induced by rituximab (anti-CD20 monoclonal antibody) in a patient refractory to cladribine," <i>Br J Haematol</i> , 2000, 109(4):900-901.				
	SR	Keating et al., "Chronic lymphocytic leukemia," <i>Semin Oncol</i> , 1999, 26:5 Suppl 14:107-114.				
MS	TR	Kuehnle et al., "CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation," <i>Blood</i> , 2000, 95(4):1502-1505.				
	UR	Kyle et al., "Waldenstrom's macroglobulinaemia: a prospective study comparing daily with intermittent oral clorambucil" <i>Br J Haematol</i> , 2000, 108:4 737-742.				
	VR	Maloney et al., "The anti-tumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (NHL) cell lines," <i>Blood</i> , 1996, 88(10):637a (#2535).				
	WR	Morrison et al., "Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains," <i>Proc Natl Acad Sci USA</i> , 1984, 81(21):6851-6855.				
	XR	Piascik, "New therapeutic monoclonal antibodies target kidney transplant rejection and cancer," <i>J Am Pharm Assoc</i> , 1998, 38(3):379-380.				
	YR	Press et al., "Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas," <i>Blood</i> , 1987, 69(2):584-591.				

Handwritten signature

9/14/2003

	ZR	Ratanatharathorn et al., "Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host-disease," <i>Annals of Internal Medicine</i> , 2000, 133:275-279.
	AAR	Reff et al., "Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20," <i>Blood</i> , 1994, 83(2):435-445.
	BBR	Treon et al., "Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy," <i>Semin Oncol.</i> , 1999, 26 (5 Suppl 14):97-106.
	CCR	Treon et al., "Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens," <i>Ann Oncol</i> , 2000, 11 Suppl 1:107-111.
Examiner		Date Considered:
		9/11/00
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.</p>		